Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma

Dermatology

Volumn 210, Issue 1, 2005, Pages 39-44

  Dummer, R ^a   Panizzon, R ^a   Bloch, P H ^a   Burg, G ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cutaneous melanoma; Swiss melanoma guidelines

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; DACARBAZINE; HISTAMINE; PEGINTERFERON; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA; VACCINE; VISCUM ALBUM EXTRACT;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MELANOMA; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SAFETY; SIDE EFFECT; SKIN CANCER; SWITZERLAND;

COMBINED MODALITY THERAPY; HUMANS; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SKIN NEOPLASMS; SWITZERLAND;

EID: 10644276906     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081482     Document Type: Review

References (28)

1. Garbe C, Dummer R, Kaufmann R, Tilgen W: Dermatologische Onkologie. Berlin, Springer, 1997.
2. Dummer R, Bosch U, Panizzon R, Bloch PH, Burg G: Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2001;203:75-80.
3. Australian Cancer Network: Guidelines for the Management of Cutaneous Melanoma. Sydney, Stone Press, 1997.
4. Panizzon RG, Guggisberg D: Klinik und Pathologie des Melanoms. Ther Umsch 1999;56:302-308.
5. Grob JJ, Bonerandi JJ: The 'ugly duckling' sign: Identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998;134:103-104.
6. Binder M, Puespoeck Schwarz M, Steiner A, Kittler H, Muellner M, Wolff K, et al: Epiluminescence microscopy of small pigmented skin lesions: Short-term formal training improves the diagnostic performance of dermatologists. J Am Acad Dermatol 1997;36(2, pt 1):197-202.
7. Haffner AC, Garbe C, Burg G, Buttner P, Orfanos CE, Rassner G: The prognosis of primary and metastasising melanoma: An evaluation of the TNM classification in 2,495 patients. Br J Cancer 1992;66:856-861.
8. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, et al: A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000;88:1484-1491.
9. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al: Final version of the American Joint Committee on Cancer Staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
10. Kaufmann R, Tilgen W, Garbe C: Malignant melanoma. Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists eV. Hautarzt 1998;48(suppl 1):S30-S38.
11. Farshad A, Burg G, Panizzon R, Dummer R: A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using grenz or soft X-rays. Br J Dermatol 2002;146:1042-1046.
12. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-399.
13. Kleeberg UR, Suciu S, Broecker EB, Ruiter DJ, Chartier C, Liénard D, et al: Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-alpha 2b versus rIFN-gamma versus Iscador M versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis. Eur J Cancer 2004;40:390-402.
14. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
15. Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, et al: High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the Multicenter Eastern Cooperative Oncology Group phase II trial E2696. J Clin Oncol 2001;19:1430-1436.
16. Eggermont AM: Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma. Expert Rev Anticancer Ther 2002;2:563-569.
17. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials. J Clin Oncol 2002;20:1818-1825.
18. Lejeune F, Lienard D, Eggermont A, Schraffordt Koops H, Kroon B, Gerain J, et al: Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma. Circ Shock 1994;43:191-197.
19. Huncharek M, Caubet JF, McGarry R: Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: A meta-analysis of 3,273 patients from 20 randomized trials. Melanoma Res 2001;11:75-81.
20. Jager D, Jager E, Knuth A: Vaccination for malignant melanoma: Recent developments. Oncology 2001;60:1-7.
21. Jansen B, Wacheck V, Heere Ress E, Schlagbauer Wadl H, Hoeller C, Lucas T, et al: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000;356:1728-1733.
22. Poo Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, et al: Follow-up recommendations for patients with American Joint Committee on Cancer stages I-III malignant melanoma. Cancer 1999;86:2252-2258.
23. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, et al: Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002;20:125-133.
24. Orfanos CE, Jung EG, Rassner G, Wolff HH, Garbe C: Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut - Stand 1993/94. Hautarzt 1994;45:285-291.
25. Garbe C, Paul A, Kohler Spath H, Ellwanger U, Stroebel W, Schwarz M, et al: Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: Recommendations for an effective follow-up strategy. J Clin Oncol 2003;21:520-529.
26. von Schulthess GK, Steinert HC, Dummer R, Weder W: Cost-effectiveness of whole-body PET imaging in non-small cell lung cancer and malignant melanoma. Acad Radiol 1998;5:S300-S302.
27. Henze G, Dummer R, Joller Jemelka HI, Boni R, Burg G: Serum S100 - A marker for disease monitoring in metastatic melanoma. Dermatology 1997;194:208-212.
28. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, et al: Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999;140:1065-1071.